
Cullinan Therapeutics, Inc.: updates and filings
Price
$8.89
November 20, 2026Market cap $577M
What Ploutos Investor adds for Cullinan Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 21% since Nov 10, 2026, when the 10-Q these figures come from was filed ($11.23 then, $8.89 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 4, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 2, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 14, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 16, 2026Shareholder voteForm8-K
- Jun 10, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 8, 2026Regulation FD disclosure, other material eventsForm8-K
- May 18, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 28, 2026Shelf registration for future offeringsFormS-3ASR
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 4, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 2, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 14, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 16, 2026 | 8-K | Shareholder vote | Document |
| Jun 10, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 8, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 18, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 2, 2020.
The full analysis
What do Cullinan Therapeutics's filings show?
The filings are where every one of Cullinan Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.